Rob Dillard

Lung Cancers Today

A new study finds that healthcare providers should focus on lung cancer screening (LCS) subjects who are less likely to remain in the program &ndash; such as those with negative low-dose CT (LDCT) exams and those who continue smoking &ndash; to maximize program adherence. The findings were published in the American Journal of Roentgenology (AJR).As the researchers noted, for people with a long history of smoking, LDCT LCS has been shown to attenuate the risk of death mortality; however, adherence to an LCS program remains appreciably lower than in randomized controlled trials. In this study, three radiologists retrospectively recorded patient demographics, smoking history and behavior changes, Lung-RADS category, PPV and NPV, and adherence to screening recommendations for 260 subjects returning for follow-up LDCT from 2014 to 2019.According to the results, 16.5% of subjects had positive scans, and of those 10.8% were Lung-RADS category 3, and 3.1% were 4A, while 2.3% were 4B, and 0.8% were 4X. Forty-three subjects (16.5%) had positive scans, of which 28/260 (10.8%) were Lung-RADS category 3, 8/260 (3.1%) were 4A, 6/260 (2.3%) were 4B, and 2/260 (0.8%) were 4X. Four study subjects were diagnosed with cancer (three lung, and one metastatic melanoma) Furthermore, the results showed that 55% of subjects were current smokers at baseline, and 46.5% smoked during the last round of LCS.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
News: Improving lung cancer CT screening performance in real-world settings &ndash; <a href="https://t.co/aqL0hwfTTS">https://t.co/aqL0hwfTTS</a>
&mdash; 7thSpace Interactive (@7thSpaceCom) <a href="https://twitter.com/7thSpaceCom/status/1283893936680054786?ref_src=twsrc%5Etfw">July 16, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Overall, the researchers observed that adherence to the program was 43%, though they noted this increased progressively the higher the Lung-RADS category. Additionally, adherence was higher in former vs. current smokers (50% vs. 36.2%; p = 0.002). Ultimately, there were only two significant independent predictors of adherence: having smoked previously and a positive (? 3) Lung-RADS category. &ldquo;Our study demonstrates that a real-world LCS can perform similar to randomized controlled trials in regard to important performance metrics,&rdquo; concluded first author Eduardo J. Mortani Barbosa, Jr., per a press release about the study.&ldquo;Such communications should emphasize that a negative LCS exam does not confer immunity to future lung cancer development,&rdquo; the authors added, &ldquo;and that continued participation in LCS, combined with smoking cessation, is essential to accrue the maximum benefits of mortality reduction amongst persons with substantial smoking history.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Improving lung cancer CT screening performance in real-world&nbsp;settings <a href="https://t.co/AhlCVs78eS">https://t.co/AhlCVs78eS</a>
&mdash; Haleplushearty.org (@haleplushearty) <a href="https://twitter.com/haleplushearty/status/1284048368428363776?ref_src=twsrc%5Etfw">July 17, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Improving lung cancer CT screening performance in real-world&nbsp;settings <a href="https://t.co/Gd0KAsdIEY">https://t.co/Gd0KAsdIEY</a>
&mdash; Boost My Wellness (@BoostMyWellness) <a href="https://twitter.com/BoostMyWellness/status/1284098338183405568?ref_src=twsrc%5Etfw">July 17, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;&nbsp;

Cecilia Brown

Beamion LUNG-1: Zongertinib Shows ‘Significant’ Activity in Patients With NSCLC Harboring HER2 Mutations

Conference Coverage

Zoldonrasib Shows ‘Encouraging’ Activity in Patients With NSCLC Harboring KRAS G12D Mutation

KRAS+ NSCLC

HARMONi-6 Meets Primary End Point of Progression-Free Survival in Squamous NSCLC

Immunotherapy in NSCLC

Stephen V. Liu, MD

MARIPOSA, LAURA, and SAVANNAH: Dr. Liu Weighs In on New Data in EGFR-Positive NSCLC

EGFR+ NSCLC

Lung Cancers Today Editors

Loïc Le Marchand, MD, PhD, MPH, to Receive AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

Lung Cancer

Alice T. Shaw, MD, PhD, to Receive AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research

ALK+ NSCLC

Latest News

How to Improve Lung Cancer Screening Programs? Focus on Patients Least Likely to Adhere, Study Finds

A new study finds that healthcare providers should focus on lung cancer screening (LCS) subjects who are less likely to remain in the program – such as those with negative ...